Ipsen, Day One ink exclusive ex─US licensing agreement to commercialize tovorafenib for most common childhood brain ...
Ipsen, a global biopharmaceutical company, and Day One Biopharmaceuticals (Day One), announced a new global partnership outside the US for tovorafenib, an oral, once-weekly, type II RAF inhibitor for paediatric low grade glioma (pLGG), the most common form …